ArticleBiomolecules2026
RT206 Couples Partial PPARα/γ Agonism with Ligand-Dependent Allosteric Potentiation of FXR Signaling in Liver Cells.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic disorder characterized by dysregulated lipid handling and bile acid signaling, processes controlled by PPARs and FXR. We report that RT206, a 2-aryloxy-3-phenyl-propanoic acid derivative, combines partial PPARα/γ agonism with positive allosteric modulation of FXR. Transactivation assays and endogenous gene-expression profiling confirmed activation of PPARα/γ-responsive genes. RT206 showed no intrinsic FXR agonism, yet it robustly potentiated FXR-dependent gene transcription in HepG2 cells in the presence of structurally distinct orthosteric agonists. Grating-coupled interferometry revealed weak interaction with apo-FXR that was enhanced by orthosteric ligands, consistent with cooperative ternary complex formation. Docking and molecular dynamics supported a model in which RT206 engages the non-orthosteric FXR S2 site, while orthosteric agonists occupy the S1 primary pocket. Comparison with guggulsterone revealed distinct predicted S2 interaction patterns associated with divergent transcriptional outcomes in vitro. In fatty acid-loaded HepG2 cells, RT206 combined with FXR agonists modulated FXR- and PPAR-regulated metabolic genes and modestly reduced neutral-lipid accumulation. These findings identify RT206 as a proof-of-principle scaffold that integrates partial PPARα/γ agonism with ligand-dependent potentiation of FXR activity and support its further evaluation in more advanced liver models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.